Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000022.xml
CC BY-NC-ND 4.0 · Gesundheitswesen
DOI: 10.1055/a-2320-2859
DOI: 10.1055/a-2320-2859
Konsensstatement
Früherkennung von Typ-1-Diabetes durch Inselautoantikörper-Screening – ein Positionspapier der Fr1daPlex-Projektleiter und -Schulungszentren, des BVKJ Bayern und PaedNetz Bayern e.V.
Early Detection Of Type 1 Diabetes By Islet Autoantibody Screening: A Position Paper Of The Fr1daplex Project Leaders And Training Centres, Bvkj Bavaria And Paednetz (Registered) Bavaria Fundref Information Deutsche Diabetes-Stiftung — Bayerisches Staatsministerium für Gesundheit und Pflege — Gesund.Leben.Bayern, LP00228 Bundesministerium für Bildung und Forschung — http://dx.doi.org/10.13039/501100002347; FKZ01KX1818 LifeScience Stiftung — HMGU 2014.01, HMGU 2016.01 The Leona M. and Harry B. Helmsley Charitable Trust — G-1911–03274, G-2112–04887, G-2103–05017 JDRF International — 1-SRA-2014–310-M-R, 3-SRA-2015–72-M-R, 3-SRA-2019- Deutscher Diabetiker-Bund — B. Braun-Stiftung — http://dx.doi.org/10.13039/100010345; BBST-D-15–00016 Landesverband Bayern der Betriebskrankenkassen — Deutsches Zentrum für Diabetesforschung (DZD e.V.) — Deutsche Diabetes-Hilfe —
Zusammenfassung
Dieses Positionspapier basiert auf der langjährigen klinischen Erfahrung und grundlagen-wissenschaftlichen Forschung der Autoren zur Diagnose und Behandlung von Kindern und Jugendlichen mit einem präsymptomatischen Frühstadium des Typ-1-Diabetes. Der Nutzen sowie potenzielle Nachteile der Früherkennung von Typ-1-Diabetes durch ein Inselautoantikörper-Screening werden kritisch diskutiert. Zudem werden die Perspektiven einer Verzögerung des Ausbruchs der klinischen Stoffwechselerkrankung durch eine Teplizumab-Behandlung adressiert. Wir sehen heute die Chance einer relevanten Verbesserung der therapeutischen Möglichkeiten und der Lebensperspektive betroffener Kinder und Jugendlicher. Wichtige nächste Schritte für die Implementierung eines Inselautoantikörper-Screenings in Deutschland sind die Fortbildung der Kinder- und Jugendärzte, die über das Screening aufklären sollen, die Etablierung von wenigen überregionalen Laboratorien, die die Testung durchführen, und die Ausweitung regionaler Kapazitäten für Schulung und Betreuung der Kinder mit einem Frühstadium des Typ-1-Diabetes.
Abstract
This position paper is based on the authors' many years of clinical experience and basic science research on the diagnosis and treatment of children and adolescents with a presymptomatic early stage of type 1 diabetes. The benefits as well as potential disadvantages of early detection of type 1 diabetes by islet autoantibody screening are critically discussed. In addition, the perspectives of delaying the onset of the clinical metabolic disease through treatment with teplizumab are addressed. Today, we see the chance for a relevant improvement in therapeutic options and life perspectives of affected children and adolescents. Important next steps for the implementation of islet autoantibody screening in Germany are the training of pediatricians who should inform families about the screening, establishment of a few transregional laboratories that carry out the test, and expansion of regional capacities for the training and care of children with an early stage of type 1 diabetes.
Schlüsselwörter
Typ-1-Diabetes - Früherkennung bei Kindern - präsymptomatisches Frühstadium - Inselautoantikörper-ScreeningKeywords
type 1 diabetes - early detection in children - presymptomatic early stage - islet autoantibody screeningPublication History
Accepted Manuscript online:
06 May 2024
Article published online:
29 July 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Kamrath C, Rosenbauer J, Eckert AJ. et al. Incidence of Type 1 Diabetes in Children and Adolescents During the COVID-19 Pandemic in Germany: Results From the DPV Registry. Diabetes Care 2022; 45: 1762-1771 DOI: 10.2337/dc21-0969.
- 2 Norris JM, Johnson RK, Stene LC. Type 1 diabetes-early life origins and changing epidemiology. Lancet Diabetes Endocrinol 2020; 8: 226-238 DOI: 10.1016/S2213-8587(19)30412-7.
- 3 Patterson CC, Karuranga S, Salpea P. et al. Worldwide estimates of incidence, prevalence and mortality of type 1 diabetes in children and adolescents: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 2019; 157: 107842 DOI: 10.1016/j.diabres.2019.107842.
- 4 Kamrath C, Monkemoller K, Biester T. et al. Ketoacidosis in Children and Adolescents With Newly Diagnosed Type 1 Diabetes During the COVID-19 Pandemic in Germany. JAMA 2020; 324: 801-804 DOI: 10.1001/jama.2020.13445.
- 5 Birkebaek NH, Kamrath C, Grimsmann JM. et al. Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 national diabetes registries. Lancet Diabetes Endocrinol 2022; 10: 786-794 DOI: 10.1016/S2213-8587(22)00246-7.
- 6 Alonso GT, Coakley A, Pyle L. et al. Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes in Colorado Children, 2010-2017. Diabetes Care 2020; 43: 117-121 DOI: 10.2337/dc19-0428.
- 7 Rawshani A, Sattar N, Franzen S. et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet 2018; 392: 477-486 DOI: 10.1016/S0140-6736(18)31506-X.
- 8 Karges B, Prinz N, Placzek K. et al. A Comparison of Familial and Sporadic Type 1 Diabetes Among Young Patients. Diabetes Care 2021; 44: 1116-1124 DOI: 10.2337/dc20-1829.
- 9 Barker JM, Goehrig SH, Barriga K. et al. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care 2004; 27: 1399-1404 DOI: 10.2337/diacare.27.6.1399.
- 10 Elding Larsson H, Vehik K, Bell R. et al. Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. Diabetes Care 2011; 34: 2347-2352 DOI: 10.2337/dc11-1026.
- 11 Winkler C, Schober E, Ziegler AG. et al. Markedly reduced rate of diabetic ketoacidosis at onset of type 1 diabetes in relatives screened for islet autoantibodies. Pediatr Diabetes 2012; 13: 308-313 DOI: 10.1111/j.1399-5448.2011.00829.x.
- 12 Jacobsen LM, Vehik K, Veijola R. et al. Heterogeneity of DKA Incidence and Age-Specific Clinical Characteristics in Children Diagnosed With Type 1 Diabetes in the TEDDY Study. Diabetes Care 2022; 45: 624-633 DOI: 10.2337/dc21-0422.
- 13 Wentworth JM, Oakey H, Craig ME. et al. Decreased occurrence of ketoacidosis and preservation of beta cell function in relatives screened and monitored for type 1 diabetes in Australia and New Zealand. Pediatr Diabetes 2022; 23: 1594-1601 DOI: 10.1111/pedi.13422.
- 14 Hekkala AM, Ilonen J, Toppari J. et al. Ketoacidosis at diagnosis of type 1 diabetes: Effect of prospective studies with newborn genetic screening and follow up of risk children. Pediatr Diabetes 2018; 19: 314-319 DOI: 10.1111/pedi.12541.
- 15 Ziegler AG, Kick K, Bonifacio E. et al. Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany. JAMA 2020; 323: 339-351 DOI: 10.1001/jama.2019.21565.
- 16 Hummel S, Carl J, Friedl N. et al. Children diagnosed with presymptomatic type 1 diabetes through public health screening have milder diabetes at clinical manifestation. Diabetologia 2023; 66: 1633-1642 DOI: 10.1007/s00125-023-05953-0.
- 17 Spiekerkötter U, Krude H. Target diseases for neonatal screening in Germany – challenges for treatment and long-term care. Dtsch Arztebl Int 2022; 119: 306-316 DOI: 10.3238/arztebl.m2022.0075.
- 18 Sassmann H, Kim-Dorner SJ, Berndt V. et al. Understanding Daily, Emotional, and Physical Burdens and Needs of Parents Caring for Children with Type 1 Diabetes. J Diabetes Res 2022; 2022: 9604115 DOI: 10.1155/2022/9604115.
- 19 Lachin JM, Bebu I, Nathan DM. et al. The Beneficial Effects of Earlier Versus Later Implementation of Intensive Therapy in Type 1 Diabetes. Diabetes Care 2021; 44: 2225-2230 DOI: 10.2337/dc21-1331.
- 20 de Wit M, Gajewska KA, Goethals ER. et al. ISPAD Clinical Practice Consensus Guidelines 2022: Psychological care of children, adolescents and young adults with diabetes. Pediatr Diabetes 2022; 23: 1373-1389 DOI: 10.1111/pedi.13428.
- 21 Cameron FJ, Scratch SE, Nadebaum C. et al. Neurological consequences of diabetic ketoacidosis at initial presentation of type 1 diabetes in a prospective cohort study of children. Diabetes Care 2014; 37: 1554-1562 DOI: 10.2337/dc13-1904.
- 22 Insel RA, Dunne JL, Atkinson MA. et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 2015; 38: 1964-1974 DOI: 10.2337/dc15-1419.
- 23 American Diabetes Association. Professional Practice Committee. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022; 45: S17-S38 DOI: 10.2337/dc22-S002.
- 24 Besser REJ, Bell KJ, Couper JJ. et al. ISPAD Clinical Practice Consensus Guidelines 2022: Stages of type 1 diabetes in children and adolescents. Pediatr Diabetes 2022; 23: 1175-1187 DOI: 10.1111/pedi.13410.
- 25 Landgraf R, Heinemann L, Schleicher E. et al. Definition, classification, diagnostics and differential diagnostics of diabetes mellitus: update 2022. Diabetol Stoffwechs 2022; 17: S98-S110 DOI: 10.1055/a-1789-5615.
- 26 Weiss A, Zapardiel-Gonzalo J, Voss F. et al. Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screening. Diabetologia 2022; 65: 2121-2131 DOI: 10.1007/s00125-022-05780-9.
- 27 Raab J, Haupt F, Scholz M. et al. Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. BMJ Open 2016; 6: e011144 DOI: 10.1136/bmjopen-2016-011144.
- 28 Amoroso M, Achenbach P, Powell M. et al. 3 Screen islet cell autoantibody ELISA: A sensitive and specific ELISA for the combined measurement of autoantibodies to GAD(65), to IA-2 and to ZnT8. Clin Chim Acta 2016; 462: 60-64 DOI: 10.1016/j.cca.2016.08.013.
- 29 Ziegler AG, Haupt F, Scholz M. et al. 3 Screen ELISA for High-Throughput Detection of Beta Cell Autoantibodies in Capillary Blood. Diabetes Technol Ther 2016; 18: 687-693 DOI: 10.1089/dia.2016.0199.
- 30 Bonifacio E, Weiss A, Winkler C. et al. An Age-Related Exponential Decline in the Risk of Multiple Islet Autoantibody Seroconversion During Childhood. Diabetes Care 2021; 44: 2260-2268 DOI: 10.2337/dc20-2122.
- 31 Ghalwash M, Dunne JL, Lundgren M. et al. Two-age islet-autoantibody screening for childhood type 1 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol 2022; 10: 589-596 DOI: 10.1016/S2213-8587(22)00141-3.
- 32 Ziegler AG, Rewers M, Simell O. et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013; 309: 2473-2479 DOI: 10.1001/jama.2013.6285.
- 33 Vehik K, Lynch KF, Schatz DA. et al. Reversion of beta-Cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study. Diabetes Care 2016; 39: 1535-1542 DOI: 10.2337/dc16-0181.
- 34 Miller KM, Foster NC, Beck RW. et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care 2015; 38: 971-978 DOI: 10.2337/dc15-0078.
- 35 Dehn-Hindenberg A, Sassmann H, Berndt V. et al. Long-term Occupational Consequences for Families of Children With Type 1 Diabetes: The Mothers Take the Burden. Diabetes Care 2021; 44: 2656-2663 DOI: 10.2337/dc21-0740.
- 36 Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit. Gesundheit der Vorschulkinder in Bayern: Ergebnisse der Schuleingangsuntersuchung zum Schuljahr 2014/2015 https://www.lgl.bayern.de/publikationen/gesundheit/doc/schuleingangsuntersuchung_2014_2015.pdf Published August 2017. Accessed December 30, 2019.
- 37 Karges B, Neu A, Hofer SE. et al. [Frequency and influencing factors of ketoacidosis at diabetes onset in children and adolescents--a long-term study between 1995 and 2009]. Klin Padiatr 2011; 223: 70-73 DOI: 10.1055/s-0030-1269884.
- 38 Segerer H, Wurm M, Grimsmann JM. et al. Diabetic Ketoacidosis at Manifestation of Type 1 Diabetes in Childhood and Adolescence-Incidence and Risk Factors. Dtsch Arztebl Int 2021; 118: 367-372 DOI: 10.3238/arztebl.m2021.0133.
- 39 Duca LM, Wang B, Rewers M. et al. Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes Predicts Poor Long-term Glycemic Control. Diabetes Care 2017; 40: 1249-1255 DOI: 10.2337/dc17-0558.
- 40 Fredheim S, Johannesen J, Johansen A. et al. Diabetic ketoacidosis at the onset of type 1 diabetes is associated with future HbA1c levels. Diabetologia 2013; 56: 995-1003 DOI: 10.1007/s00125-013-2850-z.
- 41 Duca LM, Reboussin BA, Pihoker C. et al. Diabetic ketoacidosis at diagnosis of type 1 diabetes and glycemic control over time: The SEARCH for diabetes in youth study. Pediatr Diabetes 2019; 20: 172-179 DOI: 10.1111/pedi.12809.
- 42 Lundgren M, Jonsdottir B, Elding Larsson H. et al. Effect of screening for type 1 diabetes on early metabolic control: the DiPiS study. Diabetologia 2019; 62: 53-57 DOI: 10.1007/s00125-018-4706-z.
- 43 Ghetti S, Kuppermann N, Rewers A. et al. Cognitive Function Following Diabetic Ketoacidosis in Children With New-Onset or Previously Diagnosed Type 1 Diabetes. Diabetes Care 2020; 43: 2768-2775 DOI: 10.2337/dc20-0187.
- 44 Ghetti S, Kuppermann N, Rewers A. et al. Cognitive function following diabetic ketoacidosis in young children with type 1 diabetes. Endocrinol Diabetes Metab 2023; 6: e412 DOI: 10.1002/edm2.412.
- 45 Hummel S, Friedl N, Winkler C. et al. Presymptomatic type 1 diabetes and disease severity at onset. Reply to Schneider J, Gemulla G, Bonifacio E et al. Diabetologia 2023; 66: 2389-2390 DOI: 10.1007/s00125-023-06017-z.
- 46 Schneider J, Gemulla G, Kiess W. et al. Presymptomatic type 1 diabetes and disease severity at onset. Diabetologia 2023; 66: 2387-2388 DOI: 10.1007/s00125-023-05999-0.
- 47 Steck AK, Larsson HE, Liu X. et al. Residual beta-cell function in diabetes children followed and diagnosed in the TEDDY study compared to community controls. Pediatr Diabetes 2017; 18: 794-802 DOI: 10.1111/pedi.12485.
- 48 Steffes MW, Sibley S, Jackson M. et al. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003; 26: 832-836 DOI: 10.2337/diacare.26.3.832.
- 49 Lachin JM, McGee P, Palmer JP. et al. Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes 2014; 63: 739-748 DOI: 10.2337/db13-0881.
- 50 Gubitosi-Klug RA, Braffett BH, Hitt S. et al. Residual beta cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia. J Clin Invest 2021; 131 DOI: 10.1172/JCI143011.
- 51 Forlenza GP, McVean J, Beck RW. et al. Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial. JAMA 2023; 329: 990-999 DOI: 10.1001/jama.2023.2064.
- 52 Hummel M, Ziegler AG, Roth R. Psychological impact of childhood islet autoantibody testing in families participating in the BABYDIAB study. Diabet Med 2004; 21: 324-328 DOI: 10.1111/j.1464-5491.2004.01142.x.
- 53 Kordonouri O, Lange K, Boettcher I. et al. New approach for detection of LDL-hypercholesterolemia in the pediatric population: The Fr1dolin-Trial in Lower Saxony, Germany. Atherosclerosis 2019; 280: 85-91 DOI: 10.1016/j.atherosclerosis.2018.11.011.
- 54 Müller I, Galuschka L, Marquardt E. et al. Wohlbefinden von Eltern der Kinder aus der Fr1dolin-Früherkennungsstudie in Niedersachsen/Hamburg. Diabetol Stoffwechs 2021; 16: S59 DOI: 10.1055/s-0041-1727484.
- 55 Herold KC, Bundy BN, Long SA. et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med 2019; 381: 603-613 DOI: 10.1056/NEJMoa1902226.
- 56 Sims EK, Bundy BN, Stier K. et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med 2021; 13: eabc8980 DOI: 10.1126/scitranslmed.abc8980.
- 57 Hagopian W, Ferry RJ, Sherry N. et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protege trial. Diabetes 2013; 62: 3901-3908 DOI: 10.2337/db13-0236.
- 58 Herold KC, Gitelman SE, Ehlers MR. et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013; 62: 3766-3774 DOI: 10.2337/db13-0345.
- 59 Herold KC, Gitelman SE, Willi SM. et al. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 2013; 56: 391-400 DOI: 10.1007/s00125-012-2753-4.
- 60 Perdigoto AL, Preston-Hurlburt P, Clark P. et al. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. Diabetologia 2019; 62: 655-664 DOI: 10.1007/s00125-018-4786-9.
- 61 Ramos EL, Dayan CM, Chatenoud L. et al Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes. N Engl J Med 2023; (Epub Oct 18) DOI: 10.1056/NEJMoa2308743.
- 62 Skyler JS, Krischer JP, Wolfsdorf J. et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial—Type 1. Diabetes Care 2005; 28: 1068-1076 DOI: 10.2337/diacare.28.5.1068.
- 63 Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group. Krischer JP, Schatz DA, Bundy B. et al. Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients with Type 1 Diabetes: A Randomized Clinical Trial. JAMA 2017; 318: 1891-1902 DOI: 10.1001/jama.2017.17070.
- 64 Libman I, Bingley PJ, Becker D. et al. Hydroxychloroquine in Stage 1 Type 1 Diabetes. Diabetes Care 2023; 46: 2035-2043 DOI: 10.2337/dc23-1096.
- 65 Russell WE, Bundy BN, Anderson MS. et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care 2023; 46: 1005-1013 DOI: 10.2337/dc22-2200.
- 66 Lange K. Früherkennungsuntersuchungen zum Typ-1-Diabetes aus psychologischer Sicht. Diabetologe 2018; 14: 250-256 DOI: 10.1007/s11428-018-0339-6.
- 67 Karl FM, Winkler C, Ziegler AG. et al. Costs of Public Health Screening of Children for Presymptomatic Type 1 Diabetes in Bavaria, Germany. Diabetes Care 2022; 45: 837-844 DOI: 10.2337/dc21-1648.
- 68 Wilson JM, Jungner G. Principles and practice of screening for disease. Geneva: World Health Organization; 1968. (Public Health Paper Number 34.)
- 69 Brindle P, Fahey T. Primary prevention of coronary heart disease. BMJ 2002; 325: 56-57 DOI: 10.1136/bmj.325.7355.56.
- 70 Hendriks AEJ, Marcovecchio ML, Besser REJ. et al. Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes. Diabetes Metab Res Rev 2024; 40: e3777 DOI: 10.1002/dmrr.3777.